Acadia Pharmaceuticals (ACAD)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$20.59-0.82%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put ACAD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 12% over the past year and decelerating.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskACAD’s case rests on strong recent performance and improving revenue growth, despite its unprofitable past year. Revenue growth rose from 10% in Q1 to 16% in Q2, which beat consensus. It trades at 35× P/E versus the 16× peer median. The price reflects less growth than our forecast, despite this large peer premium. A 34% next-quarter miss probability and troubled remlifanserin trials threaten the case. Peer multiples imply a price about 20% above where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. ACAD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 21 analysts currently covering ACAD (as of Oct 2026).
Based on 10 Wall Street analysts offering 12-month price targets for ACAD in the last 4 months.
Continue this research
Compare ACAD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ACAD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put ACAD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Advance remlifanserin clinical development
Drug trial results negatively impact remlifanserin development.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $20.59
The last 12 months of price, then the range of analyst 12-month targets from today’s $20.59.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Price target cut indicates potential revenue guidance issues.
Threatens: Advance remlifanserin clinical development
Negative outlook on remlifanserin impacts clinical development.
Threatens: Advance remlifanserin clinical development
Mixed trial results could hinder remlifanserin development.
FDA designation supports revenue growth potential for Remlifanserin.
Higher price target supports revenue growth expectations.
Lower price target indicates potential revenue concerns.
EU panel backing enhances product approval outlook.